New law strengthens EU pharmacovigilance system
This article was originally published in Scrip
Member state ministers have adopted new legislation intended to improve the detection and reporting of adverse drug reactions in the EU. The legislation, which is the first of the three strands of the "pharmaceutical package" to be approved, will things set up a new pharmacovigilance committee at the European Medicines Agency, impose new obligations on industry and change the way that the side-effects of medicines are reported.
You may also be interested in...
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.